ISN 2019 – Kidney benefit could help Invokana compete again
Johnson & Johnson’s Invokana has fallen behind SGLT2 rivals over amputation fears, but success in the Credence renal trial, profiled at the International Society of…
EASL 2019 – Research reminds hep B bulls that progress will be slow
Presentations from Assembly Biosciences and Spring Bank Pharmaceuticals could disappoint those hoping to see more definitive steps towards a functional cure for hepatitis…
EASL 2019 – Alnylam lays out givosiran's benefit
Full data from Alnylam's pivotal givosiran programme show a big impact for severe patients, though a case still needs to be made for a broader population.
EASL 2019 – Intercept and medics clash in Nash
Yesterday’s high-profile presentation of the Regenerate trial failed to quash concerns about Ocaliva in Nash, despite Intercept’s best attempts to polish the data.
EASL 2019 – Having filed to float, all Cirius needs now is the data
The IPO hopeful Cirius Therapeutics presented intriguing Nash data at EASL, but with the final readout from a phase IIb study looming the company’s real value is hard to…
EASL 2019 – Novo buys into Gilead’s Nash combo plan
Today’s deal will see the companies take a triple combination into clinical trials.
EASL 2019 – Intercept builds a case for Ocaliva
A look at the abstract on Intercept’s Regenerate trial seems to confirm the earlier topline result, ahead of a full data presentation later today.
EASL 2019 – Viking to push the limits of its Nash contender
Encouraging results from Viking Therapeutics’ lead Nash project have prompted the company to ask how low it can go.
AACR 2019 – Rubraca trial points to a place for Parps in pancreatic cancer
Encouraging early data from an academic trial of Clovis's Rubraca raise hopes that Parps could emerge as a more tolerable maintenance therapy for some pancreatic…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.